September 2021

No Link Between Coronary Issues, Two-Dose Hepatitis B Vaccine
While a prelicensure clinical trial of HEPLISAV-B, the two-dose adult hepatitis B vaccine, found an unanticipated numerical imbalance in acute myocardial infarction (AMI) compared with another vaccine, that was not born out in later trials. A trial found that the hazard ratio comparing the rate of AMI in the HEPLISAV-B group with the Engerix-B group was 0.92 with a 95% confidence interval of 0.63 to 1.32. Here is more information.


RZV Vaccine Protects Adult Autologous Stem-Cell Transplant Patients
Hematopoietic stem-cell transplantation impairs patients' immunity and puts them at high risk of developing herpes zoster. In the past, vaccination was not a good option because live-attenuated vaccines are generally contraindicated in the immunocompromised. Find out how that changed with the availability of the adjuvanted recombinant zoster vaccine (RZV), which now has been shown to provide significant protection. Read more.

Humoral Immunogenicity Higher in Moderna COVID-19 Vaccine Recipients
While they might be similar, messenger RNA OOVID-19 vaccines have some differences. In fact, Belgian researchers recently report a significantly higher humoral immunogenicity of the SARS-CoV-2 mRNA-1273 vaccine (Moderna) compared with the BNT162b2 vaccine (Pfizer-BioNTech) in infected as well as uninfected participants and across age categories. Here is more information.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App

Advertisement Advertisement